A.I.


Back to basics: Agentic AI and how it’s impacting clinical trial research
Since the release of OpenAI’s ChatGPT in 2022, the buzz around artificial intelligence has been impossible to ignore. From advertisements during the SuperBowl to webinars and working groups, the impact of artificial intelligence has been felt in almost every sector of our world.
But, what if we told you the most transformative shift is still on the horizon?
When ChatGPT first released it changed the way the world, including clinical research, worked. Now NVIDIA, one of the most premier companies leading the way in the development of AI, has stated that they expect the development of Agentic AI, a new type of artificial intelligence to “change the way we work in ways that parallel how different work became with the arrival of the internet.”
This means agentic AI may have a much bigger impact than even generative AI did years back.
So, if you’re curious about agentic AI, read on as we delve into its nature, differentiate it from generative AI, and reveal its transformative role in clinical research."


AI in Clinical trials - Key insights from industry experts
When OpenAI unveiled ChatGPT in November 2022, it ignited unprecedented interest in artificial intelligence. Three years later, generative AI and machine learning have caused seismic shifts in industries worldwide. The pharmaceutical industry is not left out of this shift, with Roots Analysis reporting that they expect AI within clinical trials to grow at a compound annual growth rate of 16% through 2035. This growth is driven by belief in AI’s unique ability to process and analyze massive datasets at groundbreaking speeds, identifying patterns and generating insights that would be impossible to discover through traditional methods. By leveraging these capabilities, pharmaceutical companies hope to fundamentally reimagine core aspects of clinical trials, from initial design through final data analysis.


DPHARM ‘24: Top news and trends from this year’s conference
With the 14th annual DPHARM® wrapping up, we talked to our peers across the industry to find out what the big themes and takeaways were from this year’s conference.


What happened at ASCO 2024
The annual American Society of Clinical Oncology (ASCO) meeting in Chicago highlighted the latest new molecules, methods of care, and innovation in cancer care.
As the show closed out, we checked in with our associates to see what they thought were the biggest news and trends of the show.
.png)

DIA 2023 Recap: Discover DIA’s biggest news and top trends
Over the last four days, the DIA 2023 conference has Illuminated downtown Boston as thousands of “industry, regulatory, government, academics, and patients” come together to “problem-solve, and discuss global and local challenges facing the life sciences community.”
Much like JP Morgan week and SCOPE before it, what happens at DIA often makes waves across our industry, helping set the tone for our future.
Thus, we’re providing some of the biggest and brightest takeaways from this week’s conference below.